WO2021207517A3 - Modified hr2 peptide inhibitors of coronavirus fusion - Google Patents

Modified hr2 peptide inhibitors of coronavirus fusion Download PDF

Info

Publication number
WO2021207517A3
WO2021207517A3 PCT/US2021/026416 US2021026416W WO2021207517A3 WO 2021207517 A3 WO2021207517 A3 WO 2021207517A3 US 2021026416 W US2021026416 W US 2021026416W WO 2021207517 A3 WO2021207517 A3 WO 2021207517A3
Authority
WO
WIPO (PCT)
Prior art keywords
modified
fusion
peptide inhibitors
peptides
coronavirus
Prior art date
Application number
PCT/US2021/026416
Other languages
French (fr)
Other versions
WO2021207517A2 (en
Inventor
Gene Merutka
Original Assignee
Sapience Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sapience Therapeutics, Inc. filed Critical Sapience Therapeutics, Inc.
Publication of WO2021207517A2 publication Critical patent/WO2021207517A2/en
Publication of WO2021207517A3 publication Critical patent/WO2021207517A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Abstract

Provided are modified HR2 peptides that are capable of competing with the native HR2 region of a viral spike (S) protein for binding to the HR1 region, thereby inhibiting formation of the 6-HB fusion complex and fusion with a target host cell, compositions comprising the modified HR2 peptides, and methods of inhibiting viral fusion using the HR2 peptides.
PCT/US2021/026416 2020-04-10 2021-04-08 Modified hr2 peptide inhibitors of coronavirus fusion WO2021207517A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063008469P 2020-04-10 2020-04-10
US63/008,469 2020-04-10

Publications (2)

Publication Number Publication Date
WO2021207517A2 WO2021207517A2 (en) 2021-10-14
WO2021207517A3 true WO2021207517A3 (en) 2022-01-06

Family

ID=78023205

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/026416 WO2021207517A2 (en) 2020-04-10 2021-04-08 Modified hr2 peptide inhibitors of coronavirus fusion

Country Status (1)

Country Link
WO (1) WO2021207517A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023150375A2 (en) * 2022-02-07 2023-08-10 Decoy Therapeutics Inc. Methods and compositions for treating covid infections
WO2023159113A1 (en) * 2022-02-16 2023-08-24 Greene Warner C Peptide fusion inhibitors exhibiting pan-coronavirus inhibitory activity
CN115746148B (en) * 2022-10-14 2023-09-12 中国医学科学院病原生物学研究所 Proteins with coronavirus RBD and membrane fusion inhibiting polypeptides and their use as coronavirus inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002053728A2 (en) * 2000-12-29 2002-07-11 Elitra Pharmaceuticals, Inc. Gene disruption methodologies for drug target discovery
US20160237123A1 (en) * 2008-01-23 2016-08-18 Dana-Farber Cancer Institute, Inc. Compositions and methods for the treatment of viral infections

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002053728A2 (en) * 2000-12-29 2002-07-11 Elitra Pharmaceuticals, Inc. Gene disruption methodologies for drug target discovery
US20160237123A1 (en) * 2008-01-23 2016-08-18 Dana-Farber Cancer Institute, Inc. Compositions and methods for the treatment of viral infections

Also Published As

Publication number Publication date
WO2021207517A2 (en) 2021-10-14

Similar Documents

Publication Publication Date Title
WO2021207517A3 (en) Modified hr2 peptide inhibitors of coronavirus fusion
MX2021010559A (en) Crispr-cas effector polypeptides and methods of use thereof.
WO2014080401A3 (en) Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
WO2017151940A3 (en) T-cell modulatory multimeric polypeptides and methods of use thereof
BR112019002238A2 (en) manipulated polypeptide and cell, and fermentation method.
AR056138A1 (en) PROCEDURE FOR THE RECOMBINANT EXPRESSION OF A POLYPEPTIDE
NZ606427A (en) Extended recombinant polypeptides and compositions comprising same
ATE546533T1 (en) RECOMBINANT EXPRESSION OF PROTEINS IN A DISULFIDE-BRIDGED, TWO-CHAIN FORM
WO2019191633A3 (en) Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
WO2013003045A3 (en) Procoagulant peptides and their derivatives and uses therefor
WO2006038131A3 (en) Inhibitors of infection
NO20063556L (en) HIV gp41 HR2-derived synthetic peptides and their use in treating human lack of virus immunity
WO2008121324A3 (en) Recombinant expression vector elements (reves) for enhancing expression of recombinant proteins in host cells
NZ609216A (en) Anticancer fusion protein
BRPI0720879A2 (en) microvesicle derived from tissue factor carrier (tf) carrier, composition and pharmaceutical composition comprising it, processes for its manufacture, modified tissue factor (tf) lipid protein, polynucleotide, vector, host cell and antibody.
WO2021194826A3 (en) Recombinant sars-cov-2 spike protein and uses thereof
WO2016115511A3 (en) Vegf variant polypeptide compositions
WO2007029262A3 (en) Compositions and methods using same for the detection of viruses
BR112022009670A2 (en) EFFECTOR POLYPEPTIDES OF CRISPR-CAS AND METHODS OF USE THEREOF
WO2008113970A3 (en) Peptides
MX2023002413A (en) Immunogenic coronavirus fusion proteins and related methods.
WO2018129200A3 (en) Pac1 receptor agonists (maxcaps) and uses thereof
WO2022208554A3 (en) Constructs and methods for increased expression of polypeptides
WO2023039534A3 (en) Compositions comprising a cas12i polypeptide and uses thereof
WO2018081448A8 (en) Modified immunoglobulin hinge regions to reduce hemagglutination

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21784912

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21784912

Country of ref document: EP

Kind code of ref document: A2